rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse

Biochemical and Biophysical Research Communications
Yoko MachidaNobuyuki Nukina

Abstract

Huntington disease (HD) is a fatal progressive neurodegenerative disorder associated with expansion of a CAG repeat in the first exon of the gene coding the protein huntingtin (htt). Although the feasibility of RNA interference (RNAi)-mediated reduction of htt expression to attenuate HD-associated symptoms is suggested, the effects of post-symptomatic RNAi treatment in the HD model mice have not yet been certified. Here we show the effects of recombinant adeno-associated virus (rAAV)-mediated delivery of RNAi into the HD model mouse striatum after the onset of disease. Neuropathological abnormalities associated with HD, such as insoluble protein accumulation and down-regulation of DARPP-32 expression, were successfully ameliorated by the RNAi transduction. Importantly, neuronal aggregates in the striatum were reduced after RNAi transduction in the animals comparing to those at the time point of RNAi transduction. These results suggest that the direct inhibition of mutant gene expression by rAVV would be promising for post-symptomatic HD therapy.

References

May 18, 2000·Human Molecular Genetics·R Luthi-CarterJ M Olson
Apr 12, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mihail Y MastakovMatthew J During
Apr 25, 2002·Proceedings of the National Academy of Sciences of the United States of America·Jenn-Yah YuDavid L Turner
Jun 13, 2002·Proceedings of the National Academy of Sciences of the United States of America·Robert E CampbellRoger Y Tsien
Nov 9, 2002·Gene Therapy·Anton P McCaffrey, Mark A Kay

❮ Previous
Next ❯

Citations

Dec 25, 2008·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Jiajun WeiJinzhi Xu
Sep 5, 2012·Molecular Neurobiology·Pawel M SwitonskiMaciej Figiel
May 24, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Waldy San SebastianKrystof S Bankiewicz
Sep 6, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Junghee LeeHoon Ryu
Feb 2, 2012·Expert Reviews in Molecular Medicine·Lauren M Watson, Matthew J A Wood
Dec 14, 2011·Gene Therapy·Y Zhang, R M Friedlander
Apr 5, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Nicholas R FranichDeborah Young
Oct 2, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Beverly L Davidson
Jan 25, 2013·Molecular Therapy. Nucleic Acids·Beverly L Davidson
Jul 6, 2007·Nature Clinical Practice. Neurology·Pedro Gonzalez-Alegre, Henry L Paulson
Mar 13, 2009·The Journal of Biological Chemistry·Peter O BauerNobuyuki Nukina
Aug 22, 2009·Journal of Toxicology and Environmental Health. Part a·Michael J StobartJ David Knox
Mar 20, 2009·Human Molecular Genetics·Marc S Weinberg, Matthew J A Wood
Aug 23, 2007·ILAR Journal·Shilpa RamaswamyJeffrey H Kordower
Mar 24, 2011·Nucleic Acids Research·Agnieszka FiszerWlodzimierz J Krzyzosiak
Feb 3, 2011·The Journal of Clinical Investigation·Dinah W Y Sah, Neil Aronin
Apr 15, 2011·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Amber L Southwell, Paul H Patterson
Aug 30, 2012·Molecular Neurodegeneration·Peter O BauerNobuyuki Nukina
Sep 5, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Amber L SouthwellPaul H Patterson
Oct 6, 2012·Therapeutic Delivery·Neelima ManthaNandita G Das
Oct 18, 2007·Proceedings of the National Academy of Sciences of the United States of America·M DiFigliaN Aronin
Aug 8, 2014·Molecular Therapy : the Journal of the American Society of Gene Therapy·Amber L SouthwellMichael R Hayden
Feb 10, 2009·Rinshō shinkeigaku = Clinical neurology·Nobuyuki Nukina
Sep 25, 2012·Human Molecular Genetics·Amber L SouthwellMichael R Hayden
Mar 18, 2009·Expert Opinion on Drug Delivery·Thomas M Barchet, Mansoor M Amiji
Sep 13, 2012·Progress in Neurobiology·Anna Kaplan, Brent R Stockwell
Jan 10, 2012·Neurobiology of Disease·Shilpa Ramaswamy, Jeffrey H Kordower
Feb 23, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Qingmin ChenDinah W Y Sah
Sep 30, 2009·Experimental Neurology·Edith L Pfister, Phillip D Zamore
Mar 18, 2009·Experimental Neurology·Maria Stella LombardiWilliam F Kaemmerer
Feb 24, 2007·Pharmacology & Therapeutics·Pedro Gonzalez-Alegre
Apr 1, 2009·Annals of Neurology·Valérie DrouetNicole Déglon
Jan 5, 2011·CNS Neuroscience & Therapeutics·Jelle Demeestere, Wim Vandenberghe
Jun 15, 2015·Progress in Neurobiology·Roy LardenoijeBart P F Rutten
Jul 1, 2015·Molecular Therapy. Nucleic Acids·Richard GrondinWilliam F Kaemmerer
Sep 27, 2014·Drug Discovery Today·Bruno M D C GodinhoJohn F Cryan
Mar 3, 2009·American Journal of Human Genetics·Simon C WarbyMichael R Hayden

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Related Papers

Proceedings of the National Academy of Sciences of the United States of America
Scott Q HarperBeverly L Davidson
Proceedings of the National Academy of Sciences of the United States of America
Marian DiFigliaNeil Aronin
© 2021 Meta ULC. All rights reserved